Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 10/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6911869 | 1.00 | CHRM1 (0.44) | CHRM1KMT2AKCNH2KDM4ELMNA | |
| SCHEMBL2402118 | 0.83 | ALDH1A1 (0.42) | KMT2ALMNACYP11B1CYP11B2NPC1 | |
| SCHEMBL2402123 | 0.83 | ALDH1A1 (0.42) | KMT2ALMNACYP11B1CYP11B2NPC1 | |
| SCHEMBL12065096 | 0.81 | CHRM1 (0.50) | CHRM1KMT2AKCNH2KDM4ELMNA | |
| SCHEMBL6912150 | 0.80 | CHRM1 (0.49) | CHRM1KMT2AKCNH2KDM4ELMNA | |
| SCHEMBL9978637 | 0.80 | CHRM1 (0.49) | CHRM1KMT2AKCNH2KDM4ELMNA | |
| SCHEMBL16937247 | 0.80 | CHRM1 (0.61) | CHRM1KMT2AKCNH2KDM4ELMNA | |
| SCHEMBL2400422 | 0.73 | PKM (0.39) | KMT2AKDM4ELMNAALDH1A1MAPT | |
| SCHEMBL1437273 | 0.73 | PKM (0.39) | KMT2AKDM4ELMNAALDH1A1MAPT | |
| SCHEMBL19128406 | 0.73 | KMT2A (0.43) | CHRM1KMT2AKCNH2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260418-B2 | Pyranyl aryl methyl benzoquinolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2915812-A1 | Pyranyl aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators | Merck Sharp & Dohme Corp. (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-2473048-B1 | PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20140364395-A1 | Pyranyl Aryl Methyl Benzoquinolinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME (US) | 2014-12-11 | — | — | US | disclosed |
| US-8846702-B2 | Pyranyl aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20120157438-A1 | PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157438-A1 | PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CHRM2, OPRL1 | CHRM1 1/4885KMT2A 1146/4885KCNH2 624/4885 |
| US-20140364395-A1 | Pyranyl Aryl Methyl Benzoquinolinone M1 Receptor Positive Allosteric Modulators | CHRM1, OPRL1, CHRM2 | CHRM1 1/4885KMT2A 997/4885KCNH2 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.